Advertisement

Clinical Pharmacokinetics

, Volume 51, Issue 8, pp 543–551 | Cite as

Propofol Clearance in Morbidly Obese Children and Adolescents

Influence of Age and Body Size
  • Jeroen Diepstraten
  • Vidya Chidambaran
  • Senthilkumar Sadhasivam
  • Hope R. Esslinger
  • Shareen L. Cox
  • Thomas H. Inge
  • Catherijne A. J. Knibbe
  • Alexander A. Vinks
Original Research Article

Abstract

Background and Objective

Given the alarming increase in obesity among children undergoing surgery, the main aim of this study was to characterize propofol clearance in a cohort of morbidly obese children and adolescents in relation to their age and body weight characteristics.

Methods

A prospective pharmacokinetic study in morbidly obese children and adolescents undergoing elective surgery was conducted. Serial blood samples were collected and nonlinear mixed-effects modelling using NONMEM® was performed to characterize propofol pharmacokinetics with subsequent evaluation of age and body size descriptors.

Results

Twenty obese and morbidly obese children and adolescents with a mean age of 16 years (range 9–18 years), a mean total body weight (TBW) of 125 kg (range 70–184 kg) and a mean body mass index of 46kg/m2 (range 31–63 kg/m2) were available for pharmacokinetic modelling using a two-compartment pharmacokinetic model (n = 294 propofol concentration measurements). Compared with lean body weight and ideal body weight, TBW proved to be the most predictive covariate for clearance [CL (L/min)= 1.70 × (TBW/70)0.8]. Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.

Conclusion

In the population pharmacokinetic model for propofol in morbidly obese children and adolescents, TBW proved to be the most significant determinant for clearance. As a result, it is anticipated that dosage of propofol for maintenance of anaesthesia in morbidly obese children and adolescents should be based on TBW using an allometric function.

Trial registration number (clinicaltrials.gov)

NCT00948597

Keywords

Obese Child Total Body Weight Lean Body Weight Target Control Infusion Allometric Exponent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to acknowledge the Teen Longitudinal Assessment of Bariatric Surgery team at Cincinnati Children’s Hospital Medical Center (www.Teen-LABS.org) for their support during this study. This study was funded by the Translational Research Initiative grant from Cincinnati Children’s Research Foundation, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. We would like to acknowledge financial support from NIH grant 1K24HD050387 (AAV). We also acknowledge the work of Elke H.J. Krekels, MSc during manuscript preparation.

The authors have indicated they have no financial relationships relevant to this article to disclose. The authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA 2010 Jan 20; 303(3): 242–9CrossRefPubMedGoogle Scholar
  2. 2.
    Skelton JA, Cook SR, Auinger P, et al. Prevalence and trends of severe obesity among US children and adolescents. Acad Pediatr 2009 Sep–Oct; 9(5): 322–9CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ingelfinger JR. Bariatric surgery in adolescents. N Engl J Med 2011 Oct 13; 365(15): 1365–7CrossRefPubMedGoogle Scholar
  4. 4.
    Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed 2010 Aug; 95(4): 112–7CrossRefPubMedGoogle Scholar
  5. 5.
    Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000 Mar; 92(3): 727–38CrossRefPubMedGoogle Scholar
  6. 6.
    Shafer A, Doze VA, Shafer SL, et al. Pharmacokinetics and pharmaco-dynamics of propofol infusions during general anesthesia. Anesthesiology 1988 Sep; 69(3): 348–56CrossRefPubMedGoogle Scholar
  7. 7.
    Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994 Jan; 80(1): 104–22CrossRefPubMedGoogle Scholar
  8. 8.
    Jones RD, Chan K, Andrew LJ. Pharmacokinetics of propofol in children. Br J Anaesth 1990 Nov; 65(5): 661–7CrossRefPubMedGoogle Scholar
  9. 9.
    Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006 Mar; 104(3): 466–74CrossRefPubMedGoogle Scholar
  10. 10.
    Rigby-Jones AE, Sneyd JR. Propofol and children: what we know and what we do not know. Paediatr Anaesth 2011 Mar; 21(3): 247–54CrossRefPubMedGoogle Scholar
  11. 11.
    Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993 Apr; 78(4): 657–65CrossRefPubMedGoogle Scholar
  12. 12.
    Cortinez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010 Oct; 105(4): 448–56CrossRefPubMedGoogle Scholar
  13. 13.
    van Kralingen S, Diepstraten J, Peeters MY, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet 2011 Nov 1; 50(11): 739–50CrossRefPubMedGoogle Scholar
  14. 14.
    Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44(10): 1051–65CrossRefPubMedGoogle Scholar
  15. 15.
    Peters AM, Snelling HL, Glass DM, et al. Estimation of lean body mass in children. Br J Anaesth 2011 May; 106(5): 719–23CrossRefPubMedGoogle Scholar
  16. 16.
    Development of PK/PD model for individualized propofol dosing [Clinical-Trials.gov identifier NCT00948597]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrails.gov [Accessed 2012 May 10]
  17. 17.
    Peeters MY, Prins SA, Knibbe CA, et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology 2006 Dec; 105(6): 1135–46CrossRefPubMedGoogle Scholar
  18. 18.
    Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007 Dec; 120 Suppl. 4: S164–92CrossRefPubMedGoogle Scholar
  19. 19.
    Knibbe CA, Koster VS, Deneer VH, et al. Determination of propofol in low-volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998 Mar 20; 706(2): 305–10CrossRefPubMedGoogle Scholar
  20. 20.
    Yeganeh MH, Ramzan I. Determination of propofol in rat whole blood and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997 Apr 11; 691(2): 478–82CrossRefPubMedGoogle Scholar
  21. 21.
    Beal SL, Sheiner LB, Boeckmann A. NONMEM user’s guide. San Francisco (CA): University of California, 1999Google Scholar
  22. 22.
    Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother 2000 Sep; 34(9): 1066–9CrossRefPubMedGoogle Scholar
  23. 23.
    Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24(1): 25–36CrossRefPubMedGoogle Scholar
  24. 24.
    McLeay SC, Morrish GA, Kirkpatrick CM, et al. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009 Jul; 26(7): 1626–34CrossRefPubMedGoogle Scholar
  25. 25.
    Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009; 24(1): 57–81CrossRefPubMedGoogle Scholar
  26. 26.
    Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol 2011 Jan; 71(1): 88–94CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Krekels EH, DeJongh J, van Lingen RA, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet 2011 Jan 1; 50(1): 51–63CrossRefGoogle Scholar
  28. 28.
    Marsh B, White M, Morton N, et al. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991 Jul; 67(1): 41–8CrossRefPubMedGoogle Scholar
  29. 29.
    Eleveld DJ, Proost JH, Absalom AR, et al. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet 2011 Nov 1; 50(11): 751–3CrossRefPubMedGoogle Scholar
  30. 30.
    Coppens MJ, Eleveld DJ, Proost JH, et al. An evaluation of using population pharmacokinetic models to estimate pharmacodynamic parameters for propofol and bispectral index in children. Anesthesiology 2011 Jul; 115(1): 83–93CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Jeroen Diepstraten
    • 1
  • Vidya Chidambaran
    • 2
    • 3
  • Senthilkumar Sadhasivam
    • 2
    • 3
  • Hope R. Esslinger
    • 2
  • Shareen L. Cox
    • 4
  • Thomas H. Inge
    • 3
    • 5
  • Catherijne A. J. Knibbe
    • 1
    • 6
  • Alexander A. Vinks
    • 3
    • 4
  1. 1.Department of Clinical PharmacySt. Antonius HospitalNieuwegeinthe Netherlands
  2. 2.Division of Pediatric AnesthesiaCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  3. 3.Department of Pediatrics, College of MedicineUniversity of CincinnatiCincinnatiUSA
  4. 4.Division of Clinical PharmacologyCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  5. 5.Division of Pediatric General and Thoracic SurgeryCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  6. 6.Division of PharmacologyLeiden/Amsterdam Center for Drug ResearchLeidenthe Netherlands

Personalised recommendations